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1. Where We Are 
 
Most industries as they evolve to meet market needs have embraced continuous manufacturing, a 
combination of continuous movement of components, a systems approach to designing processes 
and automated model-based control. Such an approach has led to tremendous increases in 
efficiency and quality. Among major industries, the exception is the pharmaceutical and biotech 
industry. Despite a long time acknowledgement of the benefits of continuous manufacturing in 
this industry, adoption has been slow and piecemeal. In 2007, after many years discussing 
continuous manufacturing in industry and academics, Dr. Janet Woodcock, CDER Director, 
USFDA, at the inauguration of the Novartis-MIT Center for Continuous Manufacturing challenged 
the industry to accelerate its adoption. In 2011, the first end-to-end continuous pharmaceutical 
process with automated, model-based control was run at MIT (bench scale). Thereafter followed 
three International Symposia on Continuous Manufacturing of Pharmaceuticals (ISCMP) in 2014, 
2016 and 2018, held in the US and UK. The outputs have included highly cited white papers in 
this journal on continuous pharmaceutical technology, supply chain and regulatory approaches. 
There are now six drugs, all small-molecule pharmaceuticals, that incorporate continuous 
manufacturing, but only partially and with incorporation of basic technologies. Vertex’s Orkambi 
and Symdeko, Johnson & Johnson’s Prezista, Eli Lilly’s Verzenio and Pfizer’s Daurismo have 
been approved in the US; Vertex’s Orkambi and Symkevi, Johnson & Johnson’s Prezista, and Eli 
Lilly’s Verzenio in the EU; and Johnson & Johnson’s Trmacet and Eli Lilly’s Verzenio in Japan. 
While the progress is acknowledged by the pharmaceutical community, for 12 years of 
development it is hardly admirable. The situation with biomanufacturing is similar. While 
continuous bioprocessing has been successfully implemented commercially for upstream 
(perfusion cell culture) for more than 25 years, integration of the downstream operation 
(chromatography and filtration) has not yet been demonstrated commercially. The irony is that 
none of the approved continuous processes had any major regulatory challenges related to the 
technologies, including control, and regulators keep encouraging development of new innovative 
processes, but still progress is slow. 
 
The rate of progress was particularly evident at the 2018 International Symposium on Continuous 
Manufacturing of Pharmaceuticals, where there was continued enthusiasm for continuous 
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manufacturing amongst the technical and quality community, but acknowledgement that the pace 
of implementation is slower than anticipated. The irony is that amongst this same community, 
there is industry-wide agreement that continuous pharmaceutical manufacturing would provide 
tremendous benefits, including substantial cost benefits, and regulators do not see scientific 
barriers per se and find the successes to date encouraging. However, the industry, like a car with 
its wheels stuck in mud, seems unable to get out of its rut. If only we could get on the road of 
continuous manufacturing, we would be cruising ahead, but as for now, we are spinning our 
wheels, inching forward. 
 
After the 2018 symposium, over a decade after Dr. Woodcock’s historic speech, we intended to 
provide a summary of the progress in continuous manufacturing. However, since it is evident that 
progress is slow, we decided to act more directly to try to pull the continuous manufacturing 
vehicle out of the mud. Here we provide a summary of the reasons why we believe the industry is 
stuck and how to get it unstuck. It has become evident that major policy initiatives are needed. 
 
2. A Case for Continuous Manufacturing 
 
The pharmaceutical and biotech industry has unprecedented impact on health care, providing to 
patients therapeutic solutions to unmet medical needs and broadening patient access to medicine. 
Investment in life science research continues to identify innovative therapeutic solutions to life 
threatening diseases, increasing the quality of patient’s lives. However, much remains to be done 
to assure our goal of sustained delivery of quality healthcare to more patients. Even as innovative 
new therapeutic approaches help more and more patients and lead to more personalized medicine, 
manufacturing tends to be slow to innovate. Yet manufacturing plays an essential, enabling role as 
it lies on the critical path to deliver the benefits of medical science to patients. Similarly, for 
established therapeutics, the potential of manufacturing innovation is far from achieved, and yet 
would provide tremendous benefits. Historically, in most every industry, in order to meet demand 
for quality and access, manufacturing has moved through a strategy of intensification and 
integration to continuous manufacturing. While the pharmaceutical and biotech industry has 
pursued such a strategy, and we see manufacturing innovation, the pace is slow. 
 
The metrics of progress in addressing our goal are: speed, value (with cost being an element), 
flexibility, and quality. Assurance of quality through the guaranteed provision of a safe and 
efficacious medicine is sacrosanct; speed from discovery to the patient is critical; cost across the 
discovery-to-patient lifecycle is important to the innovator, payer and patient; similarly, cost and 
quality are key post-patent for generic and biosimilar manufacturers; and flexibility to meet 
dynamic market demands across the life-cycle and beyond is essential to assure sustained access.  
The case for accelerating the pace of manufacturing innovation should be made through 
understanding the needs of the patient, the business and the regulator.  
 
 The patient need for access to medicine for acute and chronic care is clear; improved care 
is essential to enhanced quality of life and economic prosperity, in particular when faced 
with an ageing population.   The pace of scientific discovery creates an urgency to translate 
these benefits promptly to the patient. Established medicines need to be available to meet 
demand. 
J. Pharm. Sci., in press 
 
3 
 
 The industry plays a critical role as translator of scientific discovery through a journey of 
drug development, clinical evaluation and manufacturing that enables patient’s access to 
medicine. The translation is both uncertain and expensive across a lengthy timeline to 
assure safe and efficacious products for the patient. Supply chain security is critical. The 
business case for investment is essential; the development time to reach the patient and 
cost are critical. Given the market uncertainty that depends on clinical efficacy, competitive 
therapeutic strategies and payer capabilities, manufacturing flexibility across a product’s 
lifecycle is very important. The situation is analogous for established medicines, where 
risks in a highly regulated environment must correspond to potential rewards. 
 The regulator has a responsibility to the patient and to society to assure the sustained 
availability of quality products to the patient.  
 
Progress to date in implementing continuous manufacturing through process intensification and 
integration is promising. Measurement of drug critical quality attributes demonstrate a reduction 
in variance. Manufacturing cycle time through integrated process steps are dramatically shorter, 
contributing to reduced costs and increased flexibility. Process equipment size compared to batch 
is smaller, and continuous processes often incorporate fewer steps resulting in lower capital and 
operating cost and permitting greater flexibility. 
 
Given this, the tangible benefits of continuous manufacturing include: 
 
 Much faster and more economic transition from small scale clinical manufacturing to 
launch scale. 
 High potential for enhanced domestic manufacturing, which includes supply-chain and 
security benefits. This is because unlike batch processes, continuous processes do not 
depend on low-cost labor, but instead on advanced technology. 
 Improved national security by reducing dependency on foreign suppliers, with consequent 
higher quality assurance of products manufactured within the country.   
 Reduction of stockpiles for necessary medicines, which are discarded upon expiration, as 
more and more pharmaceuticals could be produced on demand. This would have a major 
impact on medical countermeasure strategy.  
 Potential for a significant improvement in process quality and consistency due to the 
unprecedented ability to maintain a state of control, low residence times, and no 
intermediate hold steps. 
 Ability to respond much more agilely to drug shortages and related challenges including 
decreasing the risk of having sole suppliers for essential medicines. 
 Lower risk of stock-outs. 
 An economically viable route for personalized medicine, of which citizens will want more 
and more.  
 Related to the previous benefit, demand will also increase for new and more complex types 
of pharmaceuticals like nucleotides, cell and gene therapy, vaccines and advanced biologic 
modalities.  
 Enhanced ability of generic competition as regulatory and economic barriers get lower. 
 
3. Why we are Stuck 
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For the most part, manufacturing innovation and the development of continuous processes and 
implementation is expensive. The value generation, including cost savings and other advantages 
as discussed above can be significant in a proper implementation that allows the value it offers to 
be realized. The challenge arises for a specific pharmaceutical or biotech product in justifying the 
transition from a known and installed (possibly fully depreciated) base technology with established 
business and regulatory processes (in multiple countries) at a given company to a new paradigm. 
There are limitations with availability of skilled personnel and existing large batch manufacturing 
capacity supporting the current operating model. Because of the significant investment needed, 
approval for a transition must be made at very senior levels in companies, including the Board. 
This means there must be significant corporate level support. However, investing in innovative 
technologies like continuous manufacturing along with new facilities is not a priority in the current 
business and regulatory environment. As medicines move to a smaller volume paradigm, the 
business case for major investments is challenging. If the whole industry could move to continuous 
manufacturing, there would be tremendous value as described above. However, the barriers are 
currently too high, particularly in light of the shifting paradigm to smaller product volumes. In 
addition, smaller companies that do not have existing manufacturing assets, are looking to Contract 
Manufacturing Organizations (CMO’s) with continuous manufacturing capabilities, but these are 
still lacking for the same reasons that major companies have been slow to adopt continuous 
manufacturing capabilities. 
 
The bottom line is that substantial benefits of continuous manufacturing remain untapped.  
 
4. How to make it Happen 
 
Given the need for companies to make major investments to harness the value of continuous 
manufacturing, we need game-changing incentives for the business as a whole. Traditionally, what 
has led to industry wide-changes are tax and regulatory incentives that affect cost and time to or 
in the market. The former have led to Ireland, Singapore and Puerto Rico as key pharmaceutical 
manufacturing hubs, and the latter include “Breakthrough Therapy” designation and additional 
patent exclusivity for pediatric indications.  
 
Other on-going activities should be supported as well but are no substitute for these game-
changers. Harmonization of regulatory processes for continuous manufacturing will avoid the 
costly steps of supplying different markets by two methods, batch and continuous, and would 
facilitate adoption. Steps are indeed being made, for example with ICH Q13, but these are still 
several years away. Acceleration of global harmonization would be beneficial. Global approval of 
manufacturing processes would be most helpful along with  having a single world-wide process 
for regulatory approval of manufacturing changes. Pre-competitive R&D activities are taking place 
and are creating opportunities, which can be seized by companies given incentives. Several nations 
support competitive and collaborative R&D programs often using national manufacturing research 
and innovation clusters with investment in the associated infrastructure and technical service 
support, routes for knowledge exchange and technology transfer and coordinated support for 
organization and institutions to develop standards. Support for skills development and training of 
existing and future workforce remain important. Whilst these are necessary aspects of creating the 
right environment for successful innovation, they are not sufficient alone and do not lead to the 
needed corporate-level decisions industry-wide.  
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Suffice it to say that the incentives that we have in mind must be for significant innovation that 
will make the business case for transition to continuous with multiple daisy-chained steps 
favorable. This innovation must follow the letter and spirit of continuous manufacturing described 
above: a combination of continuous movement of components, a systems approach to designing 
processes and automated model-based control. 
 
The kind of major incentives that we think would change the playing field are in two categories: 
 
Tax incentives: 
 
 Tax incentives for investing in pharmaceutical manufacturing innovation including 
continuous manufacturing R&D and production. 
 Tax incentives for production of pharmaceutical and biopharmaceuticals via continuous 
manufacturing for brand companies, generics, and biosimilars. 
 
Regulatory incentives that affect time:  
 
 Expedited approval process for both NDA’s and ANDA’s using continuous manufacturing 
(similar to break-through therapy status). 
 Expedited approvals for sNDA’s, in a way that incentivizes moving an existing process to 
continuous (often easier than developing a new product continuous process).  
 Consideration for exclusivity period for drugs manufactured via continuous. 
 System-based regulatory oversight instead of evidence based regulations, e.g. creation of 
rating certificates for companies based on innovation and product quality enhancements to 
enable simpler and faster regulatory approval or even waivers of certain regulatory aspects. 
 
In summary, the highly regulated pharmaceutical industry is often conservative in its approach to 
manufacturing innovation and faces complex challenges in introducing new manufacturing 
technologies. These include the belief that introducing new manufacturing technologies could 
cause delays to approval or new burdens for the business. The benefits of adoption of continuous 
manufacturing are immense, but major investments need to be made with corporate-level approval. 
In order to accelerate adoption and achieve the goals of quality, speed, cost and flexibility, we 
believe that the above combination of incentives is needed. Such an approach will help ensure that 
patients benefit from accelerated time from discovery of improved treatments to positive health 
outcomes as well as assurances in sustained, reliable, cost effective access to quality medicine. 
